ArticlePediatric research2026
Protective effects of dexpanthenol on experimental colitis in young rats: modulation of p53/BAX/BCL2 and RIPK1/RIPK3/MLKL signaling with anti-inflammatory activity.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease features chronic inflammation and epithelial barrier loss, driven by apoptosis, necroptosis, and oxidative stress. Dexpanthenol (DEX), a pantothenic acid derivative and CoA precursor, has antioxidant and tissue-protective properties, but its efficacy in colitis is unclear.
methodsThirty-two 8-week-old female Wistar albino rats were randomized to Control, Colitis, Colitis+DEX (500 mg/kg i.p. for 5 days after induction), or DEX-only (n = 8/group). Colitis was induced by intrarectal 4% acetic acid. Colonic tissues underwent H&E histology, immunohistochemistry for caspase-3, IL-6, and TNF-α, and qRT-PCR for p53, RIPK1, RIPK3, MLKL, BCL2, BAX, and caspase-9.
resultsColitis caused severe mucosal ulceration, crypt destruction, and dense inflammatory infiltration, with upregulation of pro-apoptotic (p53, BAX, caspase-9) and necroptotic (RIPK1, RIPK3, MLKL) genes, and increased IL-6 and TNF-α. DEX significantly ameliorated these changes, restoring mucosal integrity, reducing inflammatory infiltrates, and improving crypt architecture. Molecularly, DEX downregulated p53, BAX, caspase-9, RIPK1, RIPK3, and MLKL, while immunohistochemistry showed decreased caspase-3, IL-6, and TNF-α versus untreated colitis.
conclusionDEX confers robust protection in acetic-acid colitis by modulating apoptotic and necroptotic pathways and suppressing pro-inflammatory cytokines. These preclinical findings support DEX as a barrier-centric, promising epithelial-protective strategy warranting further evaluation for inflammatory bowel disease, including pediatric contexts. IMPACT: Key message: In a young-rat acetic-acid colitis model, dexpanthenol (DEX) preserved mucosal architecture and suppressed inflammation by modulating epithelial cell-death programs. Added value: DEX simultaneously downregulated apoptotic (p53, BAX, Caspase-9) and necroptotic (RIPK1, RIPK3, MLKL) pathways while restoring BCL2-a dual mechanism not previously reported in colitis models. IMPACT: Suggests that DEX may function as a barrier-centric protective strategy, potentially complementing biologics that target downstream cytokines (e.g., TNF-α, IL-6). Clinical outlook: Supports translational evaluation-especially in pediatric IBD and biologic non-responders-where durable epithelial protection is needed.
Identifiers
42380324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.